Blog
RSS FeedPosted by Michael Wonder on 04 Oct 2016
Abortion-drug company open to restarting reimbursement review process
27 September 2016 - The company that is bringing the gold standard in abortion drugs to Canada says it is “open” ...
Posted by Michael Wonder on 04 Oct 2016
NICE recommends new drug osimertinib for hundreds of people with lung cancer
4 October 2016 - Hundreds of people with lung cancer will now have access to new drug osimertinib, also known as ...
Posted by Michael Wonder on 04 Oct 2016
Did it matter that the Cancer Drugs Fund was not NICE? A retrospective review
3 October 2016 - This article reviews the means by which the Cancer Drugs Fund made recent funding decisions for cancer ...
Posted by Michael Wonder on 03 Oct 2016
NICE says no to daclizumab (Zinbryta)
3 October 2016 - The MS Trust is disappointed that NICE does not intend to recommend that daclizumab (Zinbryta) be made ...
Posted by Michael Wonder on 03 Oct 2016
NHS watchdog ready to impose hefty fees for approving drugs
1 October 2016 - NICE’s cost hike could deter start-ups and delay lifesaving treatments. ...
Posted by Michael Wonder on 02 Oct 2016
Schedule of Pharmaceutical Benefits - 1 October 2016 update
1 October 2016 - The 1 October 2016 issue of the Schedule of Pharmaceutical Benefits sees a number of new ...
Posted by Michael Wonder on 02 Oct 2016
New Zealand Pharmaceutical Schedule - 1 October 2016 update
1 October 2016 - The October 2016 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 01 Oct 2016
Breast cancer drug tamoxifen listed on Pharmaceutical Benefits Scheme
1 October 2016 - More Australian women will have access to a preventative breast cancer medicine that has been listed on ...
Posted by Michael Wonder on 01 Oct 2016
CADTH publishes initial recommendation for Afinitor (everolimus)
29 September 2016 - CADTH has published its initial recommendtation for Novartis' Afinitor. ...
Posted by Michael Wonder on 30 Sep 2016
CADTH publishes initial recommendation for Darzalex (daratumumab)
29 September 2016 - CADTH has published its initial take on the reimbursement of Darzalex for patients with multiple myeloma. ...
Posted by Michael Wonder on 30 Sep 2016
Recommendations made by the PBAC - August 2016
30 September 2016 - The outcomes from the August 2016 PBAC meeting are now available. ...
Posted by Michael Wonder on 29 Sep 2016
CADTH issues final recommendation for Lynparza
29 September 2016 - CADTH has published its final outcome for Lynparza. ...
Posted by Michael Wonder on 29 Sep 2016
CADTH posts final recommendation for Zydelig
29 September 2016 - CADTH has published its final recommendation for Zydelig for follicular lymphoma. ...
Posted by Michael Wonder on 29 Sep 2016
Cancer Drugs Fund requires further reform
27 September 2016 - Reliance on “real world” observational data undermines evidence base for clinical practice. ...
Posted by Michael Wonder on 29 Sep 2016
PBAC Guidelines review
29 September 2016 - The Department is arranging education workshops for industry organisations who will be making a PBAC submission using ...